Pancreatic Cell News 9.03 January 23, 2018 | |
| |
TOP STORYRAGE Binds Preamyloid IAPP Intermediates and Mediates Pancreatic β Cell Proteotoxicity Scientists have identified a receptor-mediated mechanism of islet amyloidosis-induced proteotoxicity. In human diabetic pancreas and in cellular and mouse models of islet amyloidosis, increased expression of the receptor for advanced glycation endproducts (RAGE) correlated with human islet amyloid polypeptide (IAPP)-induced β cell and islet inflammation, toxicity, and apoptosis. [J Clin Invest] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISDeletion of Sirt6 in pancreatic endocrine progenitor cells did not affect endocrine morphology, beta cell mass or insulin production but did result in glucose intolerance and defective glucose-stimulated insulin secretion in mice. [Diabetologia] Abstract Researchers investigated the role of K+ currents in cytokine-mediated β-cell dysfunction. Kslow currents, which control the termination of intracellular Ca2+ oscillations, were reduced following cytokine exposure. [Sci Rep] Full Article Under high glucose conditions, pharmacological activation of AMPK in isolated mouse islets or MIN6 cells by metformin or 5-aminoimidazole-4-carboxamide riboside decreased MafA protein levels and mRNA expression of insulin and GSIS-related genes. [J Biol Chem] Abstract | Full Article Researchers evaluated the effects of the oxygen-generating PDMS + CaO2 scaffold on viability, caspase-3 and caspase-7 activity, oxygen consumption rate, glucose-stimulated insulin secretion, hypoxic cell marker expression, and reactive oxygen species levels in porcine neonatal pancreatic cell clusters. [Xenotransplantation] Abstract Investigators demonstrated the ability of islet-derived endothelial cells (iECs) to induce pseudoislets (PIs) using murine insulinomas, where PI formation enhanced insulin production and glucose responsiveness. They examined the ability of iECs to spontaneously induce the formation of free-floating 3D PIs using the EndoC-βH1 human β-cell line murine MS1 iEC line. [Am J Physiol Endocrinol Metab] Abstract PANCREATIC CANCERThe authors showed that mitochondrial glutamine metabolism regulates senescence in human pancreatic ductal adenocarcinoma (PDAC) cells. Glutamine deprivation or inhibition of mitochondrial aspartate transaminase (GOT2) results in a profound induction of senescence and a suppression of PDAC growth. [Cell Death Dis] Full Article Downregulation of FEZF1-AS1 or ZNF312B significantly inhibited proliferation, colony formation, migration, and invasion of pancreatic ductal adenocarcinoma (PDAC) cells in vitro, whereas the miR-107 inhibitor abrogated the effect of dow-regulation of FEZF1-AS1 or ZNF312B in reducing oncogenic capacities of PDAC cells. [Cell Death Dis] Full Article CCR5/CCL5 Axis Interaction Promotes Migratory and Invasiveness of Pancreatic Cancer Cells In vitro experiments, such as flow cytometry, immunofluorescence and western blotting with human pancreatic cancer (PC) cell lines, showed higher expression levels of CCR5. The CCL5 activation of PC cells expressing CCR5 increased their invasive potential, while treatment with CCR5 inhibitor maraviroc inhibited the CCL5 activation. [Sci Rep] Full Article The expression of desmin, α-SMA, galectin-1, fibronectin and collagen type I in normal pancreatic, chronic pancreatitis and pancreatic cancer tissues, as well as quiescent/activated pancreatic stellate cells, was investigated. [Oncol Rep] Abstract | |
| |
REVIEWSTargeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics The authors discuss current challenges in pancreatic ductal adenocarcinoma (PDAC) therapeutics, highlight the contribution of mesenchymal/cancer stem cell plasticity to PDAC pathogenesis, and propose that targeting the drivers of plasticity will prove beneficial. [Cancers] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSBioLineRx Announces Partial Monotherapy Results from Phase IIa COMBAT Study in Pancreatic Cancer BioLineRx Ltd. announced partial results from the monotherapy portion of BL-8040’s Phase IIa COMBAT study showing that BL-8040 increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer. [Press release from BioLineRx Ltd. discussing research presented at the American Society of Clinical Oncology (ASCO) 2018 Gastrointestinal Cancers Symposium, San Francisco] Press Release Celgene Corporation announced primary endpoint findings and updated results of secondary endpoints from the Phase II international LAPACT trial of ABRAXANE® plus gemcitabine in patients with locally advanced pancreatic cancer. [Press release from Celgene Corporation discussing research presented at the American Society of Clinical Oncology (ASCO) 2018 Gastrointestinal Cancers Symposium, San Francisco] Press Release | |
| |
INDUSTRY NEWSBERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer BERG announced the FDA has granted orphan-drug designation to the company’s leading product candidate BPM31510, for the treatment of pancreatic cancer. [BERG, LLC] Press Release CytRx Corporation highlighted that aldoxorubicin licensee NantCell, Inc. has dosed the first patient in the Phase Ib portion of a Phase Ib/II clinical trial for patients with metastatic pancreatic cancer. [CytRx Corporation] Press Release | |
| |
POLICY NEWSGerman Scientists Hope for Windfall from Incoming Government Research budget could rise to 3.5% of gross domestic product if agreement struck during coalition talks holds. [Nature News] Editorial Nobel Laureate Suggests He Could Fall on Sword over Colleague’s Bogus Paper Shinya Yamanaka, who won a share of the 2012 Noble Prize in Physiology or Medicine for the discovery of induced pluripotent stem (iPS) cells, has suggested he could resign as director of Kyoto University’s Center for iPS Cell Research and Application in Japan over a fraudulent paper published by center researchers. [ScienceInsider] Editorial U.S. Scientists Breathe a Sigh of Relief as Government Shutdown to End It’s over—at least for the moment. The U.S. Senate voted 81–18 to advance legislation funding government activities, essentially ending a partial government shutdown that had moved into its third day. The House of Representatives is expected to follow suit, sending the bill to President Donald Trump for his signature. [ScienceInsider] Editorial
| |
EVENTSNEW Cold Spring Harbor (CSH): Mouse Development, Stem Cells & Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Scientist – Pancreatic Research (Medical Research Council) NEW PhD Student Position – Pancreatic Cancer Metastasis (University Medical Center Freiburg) NEW Research Program Manager – Pancreatic Cancer Program (University of Cambridge) Postdoctoral Research Scientist – Pancreatic Cancer (Columbia University) Professorship – Pancreas Development and Disease (Technischen Universität Dresden) Tenure-Track Group Leader Position – Pancreatic Cancer Biology (University of Copenhagen) Postdoctoral Research Fellow – Pancreatic Cancer (Fred Hutchinson Cancer Research Center) Postdoctoral Fellowship – Pancreatic Cancer (Memorial Sloan Kettering Cancer Center) Postdoctoral Fellowship (Memorial Sloan Kettering Cancer Center) PhD Studentship – Pancreas Development and Stem Cells (Helmholtz Zentrum München) Scientist – Diabetes and Obesity (Helmholtz Zentrum München) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|